0 rating


Marcondes NA, Raimundo FV, Vanacor R et al.

Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.

 Clin Respir J 2013 Dec 18; Epub ahead of print.

Aleksandra Norek’s review: The life- expectancy of patients with cystic fibrosis (CF) has increased in recent decades. Most CF patients have a susceptibility to vitamin D deficiency because of nutrient malabsorption associated with exocrine pancreatic failure. Supplementation according to current guidelines seems to result in less-than-expected increases in serum levels of vitamin D, thus revisions to these guidelines have recently been released (J Clin Endocrinol Metab 2012;97:1082–93). The aim of this study was to evaluate the prevalence of hypovitaminosis D in CF patients and the factors associated with serum 25-hydroxyvitamin D (25[OH]D) levels.

The investigators recruited 59 patients to this cross-sectional study. Patients had a diagnosis of CF confirmed by sweat chloride levels (≥60 mEq/L) or by identification of two mutated alleles of the CF transmembrane conductance regulator (CFTR). The nutritional status of these patients was evaluated by measuring their weight, height, and body–mass index (BMI). Serum levels of C-reactive protein, calcium phosphate, magnesium, albumin, 25(OH)D, and parathyroid hormone were also measured. Vitamin D deficiency was defined according to the US CF Foundation guidelines as a serum 25(OH)D level of <30 ng/mL. Lung function was evaluated by measuring forced vital capacity and forced expiratory volume in 1s. CF clinical severity and chest radiological scores were assessed by Shwachman-Kulczycki score and Brasfield score, respectively. The number of hospital admissions in the last year was also recorded.

Return to top


Cystic Fibrosis-Related Diabetes
Carlos E Milla
CML Diabetes
Cystic Fibrosis in the 21st Century
Nicholas J Simmonds, MD(Res), MRCP, BMBS
CML Cystic Fibrosis
Pulmonary Inflammation in Cystic Fibrosis: Impact of Innate Immunity and Estrogen
Sanjay H Chotirmall, MBBCh, BAO1, Brian J Harvey, PhD2, Noel G McElvaney, MBBCh, BAO1, and Catherine M Greene, PhD1
CML Cystic Fibrosis
Multidrug-Resistant Pseudomonas aeruginosa in Cystic Fibrosis.Part 1: Epidemiology, Mechanisms, and Clinical Implications
Michael D Parkins1,2, Christopher D Sibley1, and J Stuart Elborn3,4
CML Cystic Fibrosis
Multidrug-Resistant Pseudomonas aeruginosa in Cystic Fibrosis. Part 2: Management Considerations
Michael D Parkins1,2, Christopher D Sibley1, and J Stuart Elborn3,4
CML Cystic Fibrosis
Newborn Screening for Cystic Fibrosis: From Experiment to Routine Procedure
Jeannette E Dankert-Roelse, MD, PhD
CML Cystic Fibrosis